Kissei Pharmaceutical Co., Ltd.

This Phase 2 study tested a drug called MR13A9 in 247 Japanese adults on hemodialysis who had severe itching (uremic pruritus). Participants received either MR13A9 or a placebo intravenously. The goal was to see if the drug reduces itch intensity over 8 weeks. Results could lead …

This study tested an oral drug called KLH-2109 in 89 premenopausal Japanese women with uterine fibroids who had heavy bleeding and pain. The goal was to see if the drug could reduce bleeding and pain better than a placebo. The trial was completed and may point to a new way to man…

This completed Phase 3 trial tested a drug called MR13A9 in 178 adults on hemodialysis who suffer from severe itching (uremic pruritus). The study compared MR13A9 to a placebo to see if it reduces itch intensity, measured by a daily 0-10 rating scale. If successful, MR13A9 could …